Anne Lynch
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Retinopathy of Prematurity | 12 | 2022 | 111 | 5.790 |
Why?
| Macular Degeneration | 12 | 2023 | 152 | 4.350 |
Why?
| Complement Factor B | 7 | 2022 | 102 | 2.490 |
Why?
| Geographic Atrophy | 7 | 2023 | 51 | 2.370 |
Why?
| Neonatal Screening | 5 | 2022 | 185 | 1.830 |
Why?
| Pre-Eclampsia | 7 | 2015 | 187 | 1.800 |
Why?
| Wet Macular Degeneration | 4 | 2023 | 32 | 1.770 |
Why?
| Birth Weight | 10 | 2022 | 473 | 1.720 |
Why?
| Visual Acuity | 13 | 2023 | 275 | 1.650 |
Why?
| Premature Birth | 5 | 2017 | 304 | 1.570 |
Why?
| Retinal Drusen | 2 | 2021 | 25 | 1.530 |
Why?
| Complement Activation | 6 | 2022 | 349 | 1.480 |
Why?
| Gestational Age | 14 | 2022 | 787 | 1.400 |
Why?
| Cataract | 10 | 2023 | 194 | 1.380 |
Why?
| Complement C3a | 2 | 2019 | 33 | 1.120 |
Why?
| Phacoemulsification | 7 | 2022 | 104 | 1.110 |
Why?
| Infant, Premature | 6 | 2022 | 507 | 1.070 |
Why?
| Diabetic Retinopathy | 5 | 2023 | 156 | 0.940 |
Why?
| Cataract Extraction | 5 | 2023 | 82 | 0.910 |
Why?
| Infant, Newborn | 14 | 2022 | 5430 | 0.840 |
Why?
| Fetal Membranes, Premature Rupture | 3 | 2017 | 40 | 0.820 |
Why?
| Pregnancy | 24 | 2022 | 5854 | 0.810 |
Why?
| Weight Gain | 4 | 2019 | 511 | 0.770 |
Why?
| Retrospective Studies | 33 | 2023 | 13433 | 0.760 |
Why?
| Neurodegenerative Diseases | 1 | 2022 | 98 | 0.760 |
Why?
| Risk Factors | 19 | 2023 | 9381 | 0.730 |
Why?
| Infant, Low Birth Weight | 2 | 2017 | 130 | 0.720 |
Why?
| Pregnancy Outcome | 7 | 2015 | 364 | 0.710 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.700 |
Why?
| Choroidal Neovascularization | 1 | 2019 | 45 | 0.670 |
Why?
| Cohort Studies | 10 | 2020 | 5294 | 0.660 |
Why?
| Registries | 5 | 2021 | 2020 | 0.630 |
Why?
| Internet | 1 | 2023 | 686 | 0.630 |
Why?
| Labor, Induced | 2 | 2017 | 32 | 0.630 |
Why?
| Algorithms | 6 | 2018 | 1593 | 0.620 |
Why?
| Humans | 78 | 2023 | 122796 | 0.620 |
Why?
| Female | 59 | 2023 | 63629 | 0.620 |
Why?
| Abnormalities, Multiple | 1 | 2019 | 183 | 0.610 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 35 | 0.600 |
Why?
| Labor, Obstetric | 1 | 2017 | 55 | 0.590 |
Why?
| Retinal Detachment | 3 | 2023 | 55 | 0.580 |
Why?
| Blood Proteins | 2 | 2015 | 249 | 0.570 |
Why?
| Colorado | 10 | 2023 | 4325 | 0.560 |
Why?
| Pregnancy Trimester, First | 2 | 2015 | 128 | 0.540 |
Why?
| Insulin-Like Growth Factor I | 1 | 2017 | 288 | 0.510 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2019 | 337 | 0.500 |
Why?
| Infant | 12 | 2022 | 8523 | 0.480 |
Why?
| Infant, Very Low Birth Weight | 4 | 2019 | 71 | 0.480 |
Why?
| Placenta | 2 | 2018 | 648 | 0.480 |
Why?
| Inflammation | 4 | 2023 | 2598 | 0.460 |
Why?
| Intraoperative Complications | 4 | 2022 | 132 | 0.460 |
Why?
| Tomography, Optical Coherence | 4 | 2023 | 134 | 0.450 |
Why?
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 147 | 0.440 |
Why?
| Research Design | 1 | 2019 | 1002 | 0.440 |
Why?
| Biomarkers | 8 | 2023 | 3662 | 0.440 |
Why?
| Vitrectomy | 3 | 2021 | 58 | 0.420 |
Why?
| Body Mass Index | 4 | 2014 | 2144 | 0.410 |
Why?
| Keratotomy, Radial | 2 | 2022 | 9 | 0.410 |
Why?
| Cesarean Section | 3 | 2011 | 184 | 0.410 |
Why?
| Lens Implantation, Intraocular | 4 | 2022 | 60 | 0.400 |
Why?
| Retinal Diseases | 2 | 2023 | 81 | 0.400 |
Why?
| Myopia | 2 | 2022 | 37 | 0.390 |
Why?
| Odds Ratio | 5 | 2019 | 1043 | 0.390 |
Why?
| Pregnancy Complications | 3 | 2010 | 462 | 0.390 |
Why?
| Aged | 19 | 2022 | 20495 | 0.380 |
Why?
| Pregnancy Complications, Infectious | 2 | 2012 | 301 | 0.370 |
Why?
| Complement Activating Enzymes | 1 | 2010 | 4 | 0.370 |
Why?
| Logistic Models | 8 | 2019 | 1995 | 0.370 |
Why?
| Male | 34 | 2023 | 59639 | 0.370 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 70 | 0.360 |
Why?
| Pregnant Women | 1 | 2011 | 137 | 0.360 |
Why?
| Influenza Vaccines | 2 | 2012 | 504 | 0.350 |
Why?
| Intraocular Pressure | 4 | 2018 | 286 | 0.350 |
Why?
| Immunologic Factors | 2 | 2022 | 228 | 0.330 |
Why?
| Influenza, Human | 2 | 2012 | 566 | 0.320 |
Why?
| Obesity | 3 | 2014 | 2786 | 0.320 |
Why?
| Prospective Studies | 13 | 2023 | 6704 | 0.320 |
Why?
| Complement Pathway, Alternative | 2 | 2013 | 117 | 0.320 |
Why?
| Adult | 23 | 2020 | 32385 | 0.310 |
Why?
| Antibodies, Antiphospholipid | 3 | 1999 | 23 | 0.310 |
Why?
| Receptors, Cell Surface | 1 | 2010 | 368 | 0.310 |
Why?
| Aged, 80 and over | 10 | 2020 | 6845 | 0.310 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 839 | 0.310 |
Why?
| Sensitivity and Specificity | 3 | 2017 | 1855 | 0.300 |
Why?
| Lenses, Intraocular | 3 | 2022 | 45 | 0.300 |
Why?
| Antigens, CD | 1 | 2010 | 506 | 0.300 |
Why?
| Refraction, Ocular | 3 | 2022 | 31 | 0.290 |
Why?
| Follow-Up Studies | 9 | 2021 | 4768 | 0.280 |
Why?
| Fluorescein Angiography | 3 | 2023 | 103 | 0.280 |
Why?
| Case-Control Studies | 7 | 2022 | 3296 | 0.270 |
Why?
| Chemokine CCL5 | 2 | 2023 | 50 | 0.270 |
Why?
| Incidence | 4 | 2022 | 2527 | 0.260 |
Why?
| Glaucoma | 2 | 2018 | 214 | 0.260 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 1213 | 0.250 |
Why?
| Diabetes Mellitus | 2 | 2023 | 985 | 0.250 |
Why?
| Membrane Proteins | 1 | 2010 | 1093 | 0.230 |
Why?
| Vitreous Body | 2 | 2022 | 104 | 0.230 |
Why?
| Methylprednisolone | 1 | 2023 | 86 | 0.230 |
Why?
| Optic Neuritis | 1 | 2023 | 37 | 0.220 |
Why?
| Vision, Low | 1 | 2022 | 13 | 0.220 |
Why?
| Photorefractive Keratectomy | 1 | 2022 | 13 | 0.220 |
Why?
| Postoperative Complications | 4 | 2022 | 2301 | 0.220 |
Why?
| Vaccination | 1 | 2011 | 1241 | 0.220 |
Why?
| Keratomileusis, Laser In Situ | 1 | 2022 | 16 | 0.220 |
Why?
| Angiogenesis Inhibitors | 2 | 2023 | 223 | 0.220 |
Why?
| Proteomics | 2 | 2020 | 890 | 0.210 |
Why?
| Retinal Perforations | 1 | 2022 | 14 | 0.210 |
Why?
| Multivariate Analysis | 2 | 2019 | 1531 | 0.210 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 8 | 0.200 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.200 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 92 | 0.200 |
Why?
| Lasers, Solid-State | 1 | 2021 | 24 | 0.200 |
Why?
| Capsule Opacification | 1 | 2021 | 27 | 0.200 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.200 |
Why?
| Quality of Life | 5 | 2023 | 2457 | 0.200 |
Why?
| Aberrometry | 1 | 2020 | 9 | 0.200 |
Why?
| Complement System Proteins | 2 | 2022 | 296 | 0.200 |
Why?
| Corneal Transplantation | 1 | 2020 | 10 | 0.200 |
Why?
| Eye Banks | 1 | 2020 | 7 | 0.190 |
Why?
| Trabeculectomy | 2 | 2018 | 71 | 0.190 |
Why?
| Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.190 |
Why?
| Abortion, Spontaneous | 2 | 1999 | 95 | 0.190 |
Why?
| Optics and Photonics | 1 | 2020 | 47 | 0.190 |
Why?
| Strabismus | 1 | 2020 | 27 | 0.190 |
Why?
| Oculomotor Muscles | 1 | 2020 | 40 | 0.190 |
Why?
| Risk Assessment | 3 | 2019 | 3213 | 0.190 |
Why?
| Laser Therapy | 1 | 2021 | 105 | 0.180 |
Why?
| Surveys and Questionnaires | 6 | 2022 | 4882 | 0.180 |
Why?
| Retinal Neovascularization | 1 | 2019 | 21 | 0.180 |
Why?
| Macula Lutea | 1 | 2019 | 15 | 0.180 |
Why?
| Scleral Buckling | 1 | 2019 | 19 | 0.180 |
Why?
| Hepatitis C | 1 | 2022 | 226 | 0.180 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2020 | 58 | 0.180 |
Why?
| United States | 8 | 2020 | 13272 | 0.180 |
Why?
| Homosexuality, Male | 1 | 2020 | 176 | 0.170 |
Why?
| Uveitis, Posterior | 1 | 2019 | 12 | 0.170 |
Why?
| Pilocarpine | 1 | 2018 | 8 | 0.170 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 118 | 0.170 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2023 | 2221 | 0.170 |
Why?
| Immunity, Maternally-Acquired | 1 | 2018 | 26 | 0.170 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 1999 | 72 | 0.160 |
Why?
| Dermatitis, Atopic | 1 | 2022 | 342 | 0.160 |
Why?
| Ophthalmic Solutions | 1 | 2018 | 69 | 0.160 |
Why?
| Disease Progression | 3 | 2022 | 2546 | 0.160 |
Why?
| Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.160 |
Why?
| Middle Aged | 14 | 2021 | 28563 | 0.160 |
Why?
| Ocular Hypertension | 1 | 2018 | 60 | 0.160 |
Why?
| Trabecular Meshwork | 1 | 2018 | 77 | 0.150 |
Why?
| Metformin | 1 | 2021 | 303 | 0.150 |
Why?
| Anti-Inflammatory Agents | 1 | 2021 | 469 | 0.150 |
Why?
| Laser Coagulation | 1 | 2017 | 58 | 0.150 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.150 |
Why?
| Glycoproteins | 1 | 1999 | 323 | 0.150 |
Why?
| Parity | 1 | 2017 | 108 | 0.150 |
Why?
| Automobile Driving | 1 | 2018 | 129 | 0.150 |
Why?
| Glaucoma, Open-Angle | 1 | 2018 | 98 | 0.140 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.140 |
Why?
| Young Adult | 8 | 2019 | 11094 | 0.140 |
Why?
| Fetus | 2 | 2018 | 699 | 0.140 |
Why?
| Recovery of Function | 1 | 2019 | 610 | 0.140 |
Why?
| Time Factors | 4 | 2021 | 6682 | 0.130 |
Why?
| Time-to-Pregnancy | 1 | 2015 | 5 | 0.130 |
Why?
| Risk | 1 | 2018 | 890 | 0.130 |
Why?
| Intensive Care Units, Neonatal | 1 | 2017 | 184 | 0.130 |
Why?
| Self Report | 1 | 2018 | 730 | 0.130 |
Why?
| Phenotype | 2 | 2022 | 3070 | 0.120 |
Why?
| Mothers | 2 | 2018 | 728 | 0.120 |
Why?
| Proteins | 1 | 2020 | 953 | 0.120 |
Why?
| Obstetric Labor, Premature | 1 | 2013 | 41 | 0.120 |
Why?
| Cervical Ripening | 1 | 2013 | 8 | 0.110 |
Why?
| Sulfonamides | 1 | 2016 | 455 | 0.110 |
Why?
| Cervix Uteri | 1 | 2013 | 48 | 0.110 |
Why?
| Uterine Hemorrhage | 1 | 2013 | 36 | 0.110 |
Why?
| Pulmonary Fibrosis | 2 | 2008 | 305 | 0.110 |
Why?
| Aspirin | 1 | 2015 | 344 | 0.110 |
Why?
| Models, Statistical | 1 | 2016 | 651 | 0.100 |
Why?
| Fetal Blood | 1 | 2013 | 275 | 0.100 |
Why?
| Cross-Sectional Studies | 4 | 2020 | 4734 | 0.100 |
Why?
| Infant, Small for Gestational Age | 1 | 2012 | 74 | 0.100 |
Why?
| Tertiary Healthcare | 2 | 2022 | 29 | 0.100 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2015 | 425 | 0.100 |
Why?
| Autoantibodies | 1 | 1999 | 1353 | 0.100 |
Why?
| Severity of Illness Index | 1 | 2019 | 2784 | 0.100 |
Why?
| Endoglin | 1 | 2010 | 21 | 0.090 |
Why?
| Hypertension | 1 | 1999 | 1245 | 0.090 |
Why?
| Adiposity | 1 | 2014 | 523 | 0.090 |
Why?
| Cesarean Section, Repeat | 1 | 2009 | 11 | 0.090 |
Why?
| Child | 4 | 2022 | 19561 | 0.090 |
Why?
| Postoperative Period | 2 | 2020 | 317 | 0.090 |
Why?
| Intensive Care, Neonatal | 1 | 2009 | 43 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2023 | 537 | 0.080 |
Why?
| Placental Insufficiency | 1 | 2010 | 104 | 0.080 |
Why?
| Pregnancy Trimester, Third | 1 | 2008 | 73 | 0.080 |
Why?
| Health Status Disparities | 1 | 2011 | 217 | 0.080 |
Why?
| Academic Medical Centers | 2 | 2022 | 427 | 0.080 |
Why?
| Seasons | 1 | 2011 | 468 | 0.080 |
Why?
| Tonometry, Ocular | 2 | 2018 | 92 | 0.080 |
Why?
| Models, Biological | 1 | 2016 | 1756 | 0.080 |
Why?
| Heart Rate | 1 | 2012 | 756 | 0.080 |
Why?
| Elective Surgical Procedures | 1 | 2009 | 165 | 0.080 |
Why?
| ROC Curve | 2 | 2019 | 494 | 0.070 |
Why?
| Patient Compliance | 1 | 2011 | 561 | 0.070 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2023 | 3388 | 0.070 |
Why?
| Resuscitation | 1 | 2009 | 279 | 0.070 |
Why?
| Glyburide | 1 | 2006 | 43 | 0.070 |
Why?
| Hypoglycemic Agents | 2 | 2021 | 1055 | 0.070 |
Why?
| Predictive Value of Tests | 2 | 2008 | 1947 | 0.070 |
Why?
| Tomography, X-Ray Computed | 2 | 2008 | 2500 | 0.070 |
Why?
| Treatment Outcome | 4 | 2021 | 9692 | 0.070 |
Why?
| Ultrasonography, Doppler | 1 | 2005 | 105 | 0.070 |
Why?
| Fetal Growth Retardation | 2 | 2012 | 473 | 0.060 |
Why?
| Blood Pressure | 1 | 2012 | 1713 | 0.060 |
Why?
| Urban Health | 1 | 2004 | 89 | 0.060 |
Why?
| Vaginal Smears | 1 | 2004 | 48 | 0.060 |
Why?
| Papanicolaou Test | 1 | 2004 | 40 | 0.060 |
Why?
| Contraceptives, Oral, Combined | 1 | 2004 | 16 | 0.060 |
Why?
| Uterus | 1 | 2005 | 197 | 0.060 |
Why?
| Length of Stay | 1 | 2009 | 1077 | 0.060 |
Why?
| Ovarian Follicle | 1 | 2004 | 61 | 0.060 |
Why?
| Double-Blind Method | 4 | 2015 | 1711 | 0.060 |
Why?
| Hospitals, County | 1 | 2023 | 11 | 0.060 |
Why?
| Neuroprotection | 1 | 2023 | 31 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2011 | 1519 | 0.060 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| Adrenocorticotropic Hormone | 1 | 2023 | 153 | 0.050 |
Why?
| Lasers, Excimer | 1 | 2022 | 21 | 0.050 |
Why?
| Interleukin-4 | 1 | 2023 | 230 | 0.050 |
Why?
| Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| Pandemics | 1 | 2011 | 1401 | 0.050 |
Why?
| Diabetes, Gestational | 1 | 2006 | 285 | 0.050 |
Why?
| Alanine Transaminase | 1 | 2022 | 152 | 0.050 |
Why?
| Albumins | 1 | 2022 | 104 | 0.050 |
Why?
| Cornea | 1 | 2022 | 120 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 162 | 0.050 |
Why?
| Vision Disorders | 1 | 2022 | 134 | 0.050 |
Why?
| Intraoperative Period | 1 | 2020 | 56 | 0.050 |
Why?
| Sickness Impact Profile | 1 | 2020 | 53 | 0.050 |
Why?
| Hepacivirus | 1 | 2022 | 234 | 0.050 |
Why?
| Myotomy | 1 | 2020 | 8 | 0.050 |
Why?
| Vision, Binocular | 1 | 2020 | 15 | 0.050 |
Why?
| Intravitreal Injections | 1 | 2020 | 47 | 0.050 |
Why?
| Eye Movements | 1 | 2020 | 58 | 0.050 |
Why?
| Adolescent | 5 | 2020 | 18948 | 0.050 |
Why?
| Growth Charts | 1 | 2019 | 16 | 0.040 |
Why?
| Protective Factors | 1 | 2019 | 96 | 0.040 |
Why?
| Canada | 1 | 2020 | 355 | 0.040 |
Why?
| HIV | 1 | 2020 | 219 | 0.040 |
Why?
| beta 2-Glycoprotein I | 1 | 1999 | 3 | 0.040 |
Why?
| Antibodies, Anticardiolipin | 1 | 1999 | 5 | 0.040 |
Why?
| Remission, Spontaneous | 1 | 2019 | 37 | 0.040 |
Why?
| Pulmonary Gas Exchange | 1 | 1999 | 135 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 200 | 0.040 |
Why?
| Area Under Curve | 1 | 2019 | 303 | 0.040 |
Why?
| Positive-Pressure Respiration | 1 | 1999 | 78 | 0.040 |
Why?
| Phosphatidylserines | 1 | 1999 | 91 | 0.040 |
Why?
| Patient Acceptance of Health Care | 1 | 2004 | 707 | 0.040 |
Why?
| Child, Preschool | 3 | 2022 | 9755 | 0.040 |
Why?
| Axial Length, Eye | 1 | 2018 | 9 | 0.040 |
Why?
| Family | 1 | 2022 | 595 | 0.040 |
Why?
| Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2018 | 16 | 0.040 |
Why?
| Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| Confidence Intervals | 1 | 1999 | 339 | 0.040 |
Why?
| Referral and Consultation | 1 | 2022 | 669 | 0.040 |
Why?
| Immunoglobulin M | 1 | 1999 | 288 | 0.040 |
Why?
| North America | 1 | 2018 | 271 | 0.040 |
Why?
| Physical Examination | 1 | 2019 | 253 | 0.040 |
Why?
| Bronchodilator Agents | 1 | 1999 | 257 | 0.040 |
Why?
| Mental Health | 1 | 2022 | 571 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 690 | 0.040 |
Why?
| Transcriptome | 1 | 2022 | 774 | 0.040 |
Why?
| Equipment Design | 1 | 2018 | 533 | 0.040 |
Why?
| Interferon-beta | 2 | 2008 | 87 | 0.030 |
Why?
| Respiratory Insufficiency | 1 | 1999 | 305 | 0.030 |
Why?
| Immunoglobulin G | 1 | 1999 | 804 | 0.030 |
Why?
| Plethysmography | 1 | 2014 | 125 | 0.030 |
Why?
| Apgar Score | 1 | 1994 | 17 | 0.030 |
Why?
| Respiratory Function Tests | 2 | 2008 | 563 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2022 | 1814 | 0.030 |
Why?
| Nitric Oxide | 1 | 1999 | 884 | 0.030 |
Why?
| Mice | 1 | 2010 | 15888 | 0.030 |
Why?
| Linear Models | 1 | 2014 | 854 | 0.030 |
Why?
| Treatment Failure | 2 | 2006 | 348 | 0.030 |
Why?
| Organ Size | 1 | 2013 | 474 | 0.030 |
Why?
| Maternal-Fetal Exchange | 1 | 2012 | 157 | 0.020 |
Why?
| Body Composition | 1 | 2014 | 668 | 0.020 |
Why?
| Adipose Tissue | 1 | 2014 | 616 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2014 | 1158 | 0.020 |
Why?
| Prevalence | 1 | 1997 | 2442 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2012 | 551 | 0.020 |
Why?
| Animals | 1 | 2010 | 34133 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2008 | 551 | 0.020 |
Why?
| Fetal Macrosomia | 1 | 2006 | 57 | 0.020 |
Why?
| Rheology | 1 | 2005 | 94 | 0.020 |
Why?
| Chicago | 1 | 2004 | 43 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2008 | 1184 | 0.020 |
Why?
| Ethinyl Estradiol | 1 | 2004 | 17 | 0.020 |
Why?
| Survival Analysis | 1 | 2008 | 1325 | 0.020 |
Why?
| Levonorgestrel | 1 | 2004 | 31 | 0.020 |
Why?
| Desogestrel | 1 | 2004 | 42 | 0.020 |
Why?
| Ultrasonography, Prenatal | 1 | 2005 | 230 | 0.010 |
Why?
| Menstrual Cycle | 1 | 2004 | 115 | 0.010 |
Why?
| Women's Health | 1 | 2004 | 277 | 0.010 |
Why?
| Uterine Cervical Neoplasms | 1 | 2004 | 215 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2004 | 757 | 0.010 |
Why?
| Regression Analysis | 1 | 2003 | 1018 | 0.010 |
Why?
| Administration, Inhalation | 1 | 1999 | 664 | 0.010 |
Why?
| Oxygen | 1 | 1999 | 887 | 0.010 |
Why?
| Hypoxia | 1 | 1999 | 1003 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|